Gabelli Funds LLC Has $3.86 Million Holdings in Medtronic PLC $MDT

Gabelli Funds LLC lessened its holdings in Medtronic PLC (NYSE:MDT) by 21.4% during the 1st quarter, Holdings Channel reports. The firm owned 44,500 shares of the medical technology company’s stock after selling 12,100 shares during the period. Gabelli Funds LLC’s holdings in Medtronic were worth $3,856,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Monetary Solutions Ltd acquired a new position in Medtronic in the fourth quarter valued at approximately $27,000. Lodestone Wealth Management LLC bought a new position in Medtronic in the fourth quarter valued at approximately $27,000. Anfield Capital Management LLC grew its holdings in Medtronic by 410.7% during the 4th quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock worth $27,000 after acquiring an additional 230 shares during the period. Acumen Wealth Advisors LLC acquired a new stake in Medtronic during the 4th quarter worth $29,000. Finally, Imprint Wealth LLC bought a new stake in shares of Medtronic during the 3rd quarter valued at $31,000. Institutional investors and hedge funds own 82.06% of the company’s stock.

Insiders Place Their Bets

In other Medtronic news, EVP Harry Skip Kiil sold 4,189 shares of the business’s stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $80.44, for a total value of $336,963.16. Following the completion of the transaction, the executive vice president directly owned 37,227 shares of the company’s stock, valued at approximately $2,994,539.88. The trade was a 10.11% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.26% of the company’s stock.

Medtronic Trading Up 3.1%

MDT opened at $86.87 on Wednesday. The firm’s fifty day moving average is $80.46 and its two-hundred day moving average is $87.25. The company has a debt-to-equity ratio of 0.52, a quick ratio of 1.62 and a current ratio of 2.13. The firm has a market cap of $111.20 billion, a PE ratio of 23.29, a price-to-earnings-growth ratio of 2.26 and a beta of 0.56. Medtronic PLC has a twelve month low of $73.31 and a twelve month high of $106.33.

Medtronic (NYSE:MDT) last announced its quarterly earnings results on Wednesday, June 3rd. The medical technology company reported $1.55 earnings per share for the quarter, topping analysts’ consensus estimates of $1.54 by $0.01. Medtronic had a net margin of 13.20% and a return on equity of 14.51%. The company had revenue of $9.81 billion for the quarter, compared to analysts’ expectations of $9.62 billion. During the same period last year, the firm posted $1.62 earnings per share. The business’s quarterly revenue was up 9.9% compared to the same quarter last year. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. Equities research analysts anticipate that Medtronic PLC will post 5.94 EPS for the current year.

Medtronic Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, July 17th. Shareholders of record on Friday, June 26th were issued a dividend of $0.72 per share. This is a boost from Medtronic’s previous quarterly dividend of $0.71. This represents a $2.88 annualized dividend and a yield of 3.3%. The ex-dividend date was Friday, June 26th. Medtronic’s dividend payout ratio is presently 77.21%.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the company. Barclays increased their price target on Medtronic from $118.00 to $120.00 and gave the company an “overweight” rating in a research note on Wednesday, April 1st. Rothschild & Co Redburn decreased their price objective on Medtronic from $111.00 to $106.00 and set a “buy” rating for the company in a research note on Friday, June 5th. Evercore set a $105.00 price objective on Medtronic in a report on Monday, July 6th. Truist Financial cut their target price on Medtronic from $95.00 to $86.00 and set a “hold” rating on the stock in a research note on Thursday, June 4th. Finally, The Goldman Sachs Group reduced their target price on Medtronic from $84.00 to $83.00 and set a “neutral” rating on the stock in a report on Thursday, June 4th. Eighteen analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $98.83.

More Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic completed its $650 million acquisition of SPR Therapeutics and launched the ViaVerte system at ASPN 2026. The deal expands the company’s non-opioid pain-management portfolio and could provide a new avenue for growth in pain therapy. Medtronic Completes $650 Million SPR Deal And Launches ViaVerte
• Positive Sentiment: Brokerages have assigned Medtronic an average “Moderate Buy” recommendation, indicating that analysts generally see upside or support at current valuation levels. Medtronic Given Average Recommendation of Moderate Buy
• Neutral Sentiment: Valuation analysis suggests MDT is near fair value on a discounted-cash-flow basis but may screen as undervalued on earnings multiples. Shares are near a five-year low after an approximately 25% five-year decline, which may attract value investors, though the analysis notes execution and growth risks. Medtronic Stock May Be Fairly Valued As Shares Sit Near A 5 Year Low
• Neutral Sentiment: MDT recently outperformed the broader market in a session that ended at $84.22, reflecting improving short-term momentum but offering no major fundamental catalyst by itself. Medtronic Outpaces Stock Market Gains
• Negative Sentiment: Medtronic initiated a voluntary Class II recall of its DLP One-Piece Pediatric Arterial Cannula after two complaints involving loose foreign material with trace blood levels. The recall may raise product-quality, regulatory and reputational concerns, although its impact on company-wide results is not yet clear. Is Medtronic Fairly Valued After Its Pediatric Cannula Recall?

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).